Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell CORT and other ETFs, options, and stocks.

About CORT

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
500
Employees500
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
500
Employees500

CORT Key Statistics

Market cap
8.49B
Market cap8.49B
Price-Earnings ratio
88.79
Price-Earnings ratio88.79
Dividend yield
Dividend yield
Average volume
522.42K
Average volume522.42K
High today
$81.41
High today$81.41
Low today
$78.40
Low today$78.40
Open price
$78.59
Open price$78.59
Volume
541.71K
Volume541.71K
52 Week high
$117.33
52 Week high$117.33
52 Week low
$49.00
52 Week low$49.00

Stock Snapshot

Corcept Therapeutics(CORT) stock is priced at $80.28, giving the company a market capitalization of 8.49B. It carries a P/E multiple of 88.79.

On 2025-11-26, Corcept Therapeutics(CORT) stock moved within a range of $78.40 to $81.41. With shares now at $80.28, the stock is trading +2.4% above its intraday low and -1.4% below the session's peak.

Trading volume for Corcept Therapeutics(CORT) stock has reached 541.71K, versus its average volume of 522.42K.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

The stock's 52-week range extends from a low of $49.00 to a high of $117.33.

CORT News

TipRanks 21h
Corcept Therapeutics: Poised for Growth with Relacorilant’s Launch and Strong Market Positioning

Analyst Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Corcept Therapeutics and keeping the price target at $145.00. TipRanks Black Frid...

Simply Wall St 2d
Is Corcept Therapeutics Fairly Priced After Recent Partnership and 54.7% Share Surge in 2025?

Wondering if Corcept Therapeutics is really worth its recent buzz, or if the market might be missing something about this fast-growing biotech? You are not alon...

Is Corcept Therapeutics Fairly Priced After Recent Partnership and 54.7% Share Surge in 2025?
Simply Wall St 6d
Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics

Wolfe Research recently initiated coverage on Corcept Therapeutics with a Peerperform rating, highlighting both the company’s ongoing patent litigation and anti...

Patent Uncertainty and Drug Launch Timing Poise a Pivotal Question for Corcept Therapeutics

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.